Abstract:FTY720 is a promising drug in attenuating multiple sclerosis, prolonging survival of organ allograft, and many other protective effects. Its mechanism of action is considered to be mediated by the internalization of sphingosine 1-phosphate receptors (S1PRs). In the current study, we investigated the efficacy of FTY720 in Non-Obese Diabetic (NOD) mice, serving as a model of Dry Eye Disease (DED). NOD mice were divided into six study groups, i.e., FTY720-treated groups with 3 concentrations of FTY720 (0.05%, 0.005%, and 0.001%), 0.05% Cyclosporin A (CsA) treated group, normal saline treated group, and no treatment control group. FTY720 was reconstituted with normal saline and prepared as eye drop. The stability and production of tear film was measured by Tear Break up Time test (TBUT) and phenol red cotton thread test (PRCTT), respectively. Tear fluid washings were collected and assessed by ELISA. Cytokines were detected in lacrimal glands by RT-PCR. Inflammation in conjunctiva was assessed by immunohistochemistry, goblet cells and conjunctival epithelia were examined and evaluated by impression cytology. Our results indicated that FTY720 had a significantly therapeutic effect in NOD mice. After FTY720 intervention, TBUT and PRCTT data were greatly improved (p < 0.01), the interleukin 1 beta (IL-1 beta) level was markedly decreased in tear fluid washings compared to control and normal saline groups after 2 weeks (Control: 1.06 +/- 0.12, Normal saline:0.97 +/- 0.09 pg/ml, CsA:0.22 +/- 0.02 pg/ml, 0.001% FTY720:0.23 +/- 0.02 pg/ml, 0.005% FTY720:0.14 +/- 0.03 pg/ml, 0.05% FTY720: 0.18 +/- 0.03 pg/ml. CsA group and 3 FTY720 groups VS. control group and normal saline groups: p < 0.01). Proinflammatory factors were greatly decreased in lacrimal glands (p < 0.01). Leukocytes were identified and markedly decreased in conujnctiva (p < 0.01), inflammatory reaction of DED was greatly relieved. More importantly, the goblet cells were largely restored and ocular surface lesions were significantly ameliorated (p < 0.01). Thus, we observed FTY720 alleviated DED in NOD mice by inhibiting leukocytes, the function of ocular surface tissue in NOD mice was partially restored via inhibiting ocular surface inflammation and increasing the density of goblet cells and conjunctival epithelia. FTY720 may offer a novel strategy for the treatment of inflammatory disorders in the ocular surface. (C) 2015 Elsevier Ltd. All rights reserved.

FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus

Preliminary Study of Treating BXSB Spontaneous Lupus Model by FTY720

Effects of FTY720 on BXSB Lupus‐prone Mice: a Preliminary Study

Fty720 Attenuates 6-Ohda-associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models

E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis

Diffusion Tensor Imaging Detects Treatment Effects of FTY720 in Experimental Autoimmune Encephalomyelitis Mice

Small Molecule Compound K-7174 Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice

FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3 Inflammasome Activation

FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.

Fingolimod Targets Cerebral Endothelial Activation To Block Leukocyte Recruitment In The Central Nervous System

Microglia orchestrate synaptic and neuronal stripping: Implication in neuropsychiatric lupus

Fingolimod (fty720) Attenuates Social Deficits, Learning and Memory Impairments, Neuronal Loss and Neuroinflammation in the Rat Model of Autism

FTY720 attenuates acute colitis via colonic T cells reduction and inhibition of M1 macrophages polarization independent of CCR2-mediated monocytes input

FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-β signalling in fibroblasts

Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells

FTY720 Ameliorates Sclerodermatous Chronic GVHD by Expansion of Splenic Regulatory Cells and Inhibition of Skin Immune Cell Infiltration

FTY720 Prevents Spatial Memory Impairment in a Rat Model of Chronic Cerebral Hypoperfusion via a SIRT3-Independent Pathway

A New Benzenediamine Derivative Modulates Toll-like Receptors-Induced Myeloid Dendritic Cells Activation and Ameliorates Lupus-Like Syndrome in MRLlpr/lpr Mice.

Neuronal NR4A1 Deficiency Drives Complement-Coordinated Synaptic Stripping by Microglia in a Mouse Model of Lupus

Fty720 Ameliorates Dry Eye Disease in Nod Mice: Involvement of Leukocytes Inhibition and Goblet Cells Regeneration in Ocular Surface Tissue

A Benzenediamine Derivative Fc-99 Attenuates Lupus-Like Syndrome in MRL/lpr Mice Related to Suppression of Pdc Activation.